The document discusses cross matching procedures for blood transfusions. It describes the two types of cross matching - major and minor. The major cross match mixes the donor's red blood cells with the patient's serum to check for antibodies that could cause hemolytic transfusion reactions. The minor cross match mixes the donor's serum with the patient's cells. Procedures like saline, albumin phase, and Anti-Human Globulin (AHG) are described for detecting various antibodies. Cross matching is important to ensure blood compatibility and prevent transfusion reactions.
An absolute eosinophil count is a blood test that measures the number of one type of white blood cells called eosinophils.
Eosinophils become active when you have certain allergic diseases, infections, and other medical conditions.
how to select a healthy donor & care of donor .A healthy donor is one of the most vital part of transfusion medicine for safe transfusion of blood & blood product
It is fluid which is present
in the pericardial cavity of
heart b/w parietal pericardium n visceral pericardium.
The pericardial cavity is a
potential space lined by
mesothelium of the visceral n parietal pericardium.
An absolute eosinophil count is a blood test that measures the number of one type of white blood cells called eosinophils.
Eosinophils become active when you have certain allergic diseases, infections, and other medical conditions.
how to select a healthy donor & care of donor .A healthy donor is one of the most vital part of transfusion medicine for safe transfusion of blood & blood product
It is fluid which is present
in the pericardial cavity of
heart b/w parietal pericardium n visceral pericardium.
The pericardial cavity is a
potential space lined by
mesothelium of the visceral n parietal pericardium.
The Compatibility can be determined by matching the different blood group systems, such as ABO and Rh system, and/or by directly testing for the presence of antibodies against a sample of donor tissues or blood.
The main purpose of this test is to distinguish the appearance of antibodies in the recipient against the red blood cells of the donor. These antibodies can be found on the surface of red blood cells of the donor after transfusion.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
3. CROSS MATCHING :
The compatibility testing includes, ABO
and Rh typing on the donor and recipient
blood samples, screening of donor’s and
patient’s sera for unexpected alloantibody,
and finally a cross-match.
PREPARED BY MITALI
3
4. TYPES OF CROSS MATCHING :
The cross-matching is of two types: major
cross-match and minor crossmatch.
Major cross-match When the donor’s red
cells and the patient’s serum is mixed and
tested, it is called major cross-match:
Donor’s cells + Patient’s serum.
Minor cross-match Donor’s serum +
Patient’s cells.
PREPARED BY MITALI
4
5. IMPORTANCE OF EACH TYPE:
The major crossmatch involves testing the
patient’s serum with donor cells to
determine whether the patient has an
antibody which may cause a hemolytic
transfusion reaction or decreased cell
survival of donor cells. This is the most
important cross-match.
The minor crossmatch involves testing
the patients cells with donor plasma to
determine whether there is an antibody in
the donor’s plasma directed against an
antigen on the patient’s cells.
PREPARED BY MITALI
5
6. SAMPLE COLLECTION :
The blood sample from the patient must be collected in both, EDTA and plain tubes, in order to
perform forward and reverse grouping. If detection of alloantibodies in the patient’s serum is to be
carried out, at least 5 ml blood sample in a plain vial is required. The donor sample is collected from the
pilot tube or one of the segments of the tube attached to the bag. The number given on the segment
should always be recorded for proper identification
PREPARED BY MITALI
6
7. PROCEDURE FOR THE CROSS MATCHING FOR WHOLE BLOOD
TRANSFUSION :
Saline technique
This technique is designed to detect IgM antibodies of ABO system.
•Label two test tubes, one A for major and one B for minor cross-match.
•Place 2 drops of patient’s serum in the tube labelled A and 2 drops of donor’s serum in the tube labelled B.
•Add 1 drop of 2-5% (tomato coloured) cell suspension of the donor in tube A and 1 drop of patient’s cells in tube B.
•Mix and incubate at RT for 10 minutes.
•Centrifuge at 1000 rpm for 1-2 minutes.
•Place 1 drop from each tube A and B on two separate glass slides and examine under microscope.
•Put a drop of saline on each slide to disperse the rouleaux.
•Record the results.
PREPARED BY MITALI
7
8. INTERPRETATION :
Haemolysis or even weak agglutination (2-3
cells sticking together) is considered
incompatible
PREPARED BY MITALI
8
9. ALBUMIN PHASE & AHG METHOD:
The addition of 22% albumin acts as an enhancing medium. When it is incorporated
along with IAT in cross-matching, it helps in detection of weak reacting antibodies and
also IgG antibodies reacting at 37°C.
PROCEDURE FOR ALBUMIN PHASE
Add 1-2 drops of 22% bovine albumin to the serum cell mixture.
Incubate at 37°C for 30 minutes.
Centrifuge at 1000 rpm for 1 minute.
Haemolysis or agglutination at this stage indicates presence of weak reacting (IgG)
antibodies.
Wash the cells three times with normal saline and discard the supernatant completely
every time.
PREPARED BY MITALI
9
10. AHG METHOD :
Add 2 drops of AHG serum.
Centrifuge at 1000 rpm for 1 minute.
Dislodge the button gently and examine for agglutination.
Haemolysis or agglutination at this stage indicates presence of IgG
antibodies.
PREPARED BY MITALI
10
11. PROCEDURE FOR ISSUING BLOOD UNITS
The technician while issuing the blood must ensure that the label on the unit contains the following information:
Donor’s registration number.
Donor’s blood group (ABO and Rh).
Date of collection.
Date of expiry.
Stamp designating HBsAg, anti-HCV, HIV1 and HIV2, VDRL/RPR/TPHA and Malaria (anti-HBc and also HTLV1, where
applicable) negative.
Name of the person who cross-matched blood.
Name of the patient/ recipient.
Patient’s blood group.
Date and time of issue.
Recheck the date of expiry, screening status, donor’s and patient’s identification and the blood unit for abnormal colour or signs of
haemolysis.
PREPARED BY MITALI
11